NYSE:DNA Ginkgo Bioworks (DNA) Stock Price, News & Analysis $12.22 -1.24 (-9.21%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$12.82 +0.60 (+4.95%) As of 08/8/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ginkgo Bioworks Stock (NYSE:DNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ginkgo Bioworks alerts:Sign Up Key Stats Today's Range$12.09▼$14.0550-Day Range$7.11▼$14.9252-Week Range$5.00▼$16.85Volume1.97 million shsAverage Volume1.74 million shsMarket Capitalization$715.24 millionP/E RatioN/ADividend YieldN/APrice Target$8.50Consensus RatingHold Company Overview Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. Read More Ginkgo Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreDNA MarketRank™: Ginkgo Bioworks scored higher than 25% of companies evaluated by MarketBeat, and ranked 824th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingGinkgo Bioworks has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGinkgo Bioworks has received no research coverage in the past 90 days.Read more about Ginkgo Bioworks' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ginkgo Bioworks are expected to grow in the coming year, from ($10.02) to ($5.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ginkgo Bioworks is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ginkgo Bioworks is -2.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGinkgo Bioworks has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted27.10% of the float of Ginkgo Bioworks has been sold short.Short Interest Ratio / Days to CoverGinkgo Bioworks has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Ginkgo Bioworks has recently decreased by 13.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGinkgo Bioworks does not currently pay a dividend.Dividend GrowthGinkgo Bioworks does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted27.10% of the float of Ginkgo Bioworks has been sold short.Short Interest Ratio / Days to CoverGinkgo Bioworks has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Ginkgo Bioworks has recently decreased by 13.98%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.71 News SentimentGinkgo Bioworks has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Ginkgo Bioworks this week, compared to 5 articles on an average week.Search InterestOnly 6 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,667.00 in company stock.Percentage Held by InsidersOnly 9.72% of the stock of Ginkgo Bioworks is held by insiders.Percentage Held by Institutions78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ginkgo Bioworks' insider trading history. Receive DNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. Email Address DNA Stock News HeadlinesSteven P. Coen Sells 1,084 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) StockJuly 22, 2025 | insidertrades.comGinkgo Bioworks Holdings, Inc. (NYSE:DNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.33August 10 at 2:23 PM | finance.yahoo.comAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. While the crowd buys Bitcoin outright, trader Larry Benedict is using a method called “Bitcoin Skimming” to target 6x, 9x, even 22x bigger profits. He reveals how it works in a free video.August 10 at 2:00 AM | Brownstone Research (Ad)Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call TranscriptAugust 8 at 4:01 AM | seekingalpha.comGinkgo Bioworks Holdings, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 8 at 3:20 AM | seekingalpha.comGinkgo Bioworks Reports Second Quarter 2025 Financial ResultsAugust 7 at 5:01 PM | prnewswire.comGinkgo Bioworks awarded $4.66M contract by PNNLAugust 1, 2025 | finance.yahoo.comGinkgo Bioworks Announces Date of Second Quarter 2025 Results PresentationJuly 31, 2025 | prnewswire.comSee More Headlines DNA Stock Analysis - Frequently Asked Questions How have DNA shares performed this year? Ginkgo Bioworks' stock was trading at $9.82 on January 1st, 2025. Since then, DNA shares have increased by 24.4% and is now trading at $12.22. How were Ginkgo Bioworks' earnings last quarter? Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its quarterly earnings results on Thursday, August, 7th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. The firm earned $49.60 million during the quarter, compared to analysts' expectations of $41.60 million. Ginkgo Bioworks had a negative trailing twelve-month return on equity of 41.63% and a negative net margin of 136.56%. Read the conference call transcript. Who are Ginkgo Bioworks' major shareholders? Top institutional investors of Ginkgo Bioworks include Forbes J M & Co. LLP (1.84%), Geode Capital Management LLC (1.60%), Prescott Group Capital Management L.L.C. (1.33%) and Exchange Traded Concepts LLC (0.50%). Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Harry Sloan, Marie E Fallon and Steven P Coen. View institutional ownership trends. How do I buy shares of Ginkgo Bioworks? Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ginkgo Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/07/2025Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:DNA CIK1830214 Webwww.eagleequityptnrs.com Phone877-442-5362FaxN/AEmployees640Year FoundedN/APrice Target and Rating Average Price Target for Ginkgo Bioworks$8.50 High Price Target$10.00 Low Price Target$7.00 Potential Upside/Downside-30.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($9.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$547.03 million Net Margins-136.56% Pretax Margin-199.02% Return on Equity-41.63% Return on Assets-21.67% Debt Debt-to-Equity RatioN/A Current Ratio4.88 Quick Ratio4.88 Sales & Book Value Annual Sales$227.04 million Price / Sales3.15 Cash FlowN/A Price / Cash FlowN/A Book Value$13.17 per share Price / Book0.93Miscellaneous Outstanding Shares58,530,000Free Float52,843,000Market Cap$715.24 million OptionableOptionable Beta1.50 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:DNA) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersI trusted Trump and got screwedPorter Stansberry says he got one thing wrong—and now millions of Americans could pay the price. After warning...Porter & Company | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.